ANIK

Anika Therapeutics, Inc.

Company Overview

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

SectorHealthcare
IndustryMedical - Specialties
Market Cap$278.5M
Employees235
CEOStephen D. Griffin

Valuation

Current Price$20.81
Fair Value?$000.00
Valuation?No valuation
Hist. PE ?22.77
EPS (TTM) ?-0.28
Forward EPS Growth ?47.57%
Historical Growth ?-3.39%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro

Price

EPS

Revenue

Equity

Pro

Available on the Pro plan

Free Cash Flow

Pro

Available on the Pro plan

Long Term Debt

Pro

Available on the Pro plan

Net Profit

Pro

Available on the Pro plan

Shares Outstanding

Pro

Available on the Pro plan

Last updated: 9/5/2026, 5:55:13 PM